ZURICH, Switzerland, December 2025 – Venture Valuation/Biotechgate (the “Company”) a leader in life science valuation and data solutions, is pleased to announce its participation in JPM Week 2026, taking place in San Francisco this January. The week, centered around the J.P. Morgan Healthcare Conference, is one of the most significant gatherings in the life sciences calendar.
During the week, the Company will attend the following events:
- Sachs 11th Annual Oncology Innovation Forum – January 10, 2026
- Sachs 9th Annual Neuroscience Innovation Forum – January 11, 2026
- Biotech Showcase – January 12-14, 2026
- RESI JPM 2026 – January 12-13, 2026
Speaking about JPM Week, Venture Valuation founder and CEO, Dr. Patrik Frei, said:
“JPM Week is the most important event in the life sciences calendar, and we are excited to participate as well as connect and re-connect with fellow life science professionals. Especially providing our HelloPartnering system for the RESI JPM conference highlights our commitment to supporting the life sciences ecosystem with connecting Biotech with investors, pharma and other stakeholders.”
The Company’s representatives, Johan, Veronika and Patrik, welcome the opportunity to connect with attendees during these events and provide insights into solutions for the ever-evolving biotech landscape. Registered attendees can schedule a one-on-one meeting with the Company’s delegates using the conference portals. Alternatively, they can get in touch at contact@venturevaluation.com.
About Venture Valuation: Venture Valuation was founded in 1999 based on profound research work by the founder and CEO, Dr. Patrik Frei, at the University of St. Gallen (HSG) and the Swiss Federal Institute of Technology in Lausanne (EPFL). The company has remained true to its mission: the independent assessment and valuation of companies, products and assets.
The focus lies on life sciences companies including pharmaceuticals, biotechnology (Biotech), medical technology (MedTech), diagnostic and digital health. Clients include both, investors as well as finance-seeking companies themselves, and are domiciled on almost all continents. Over the course of more than two decades, key strengths and expertise have been built in the life sciences industry with over 1,000 valuations.
About Biotechgate: Biotechgate is a leading business development and licensing database for the entire life science industry, offering a wealth of information on over 60,000 life science company profiles. Thanks to its unique data-sourcing process, the profiles include company descriptions, contact information, product pipeline information, financing rounds, and management details, making it an invaluable resource for life sciences start-ups, pharma companies, investors, and other industry professionals. Biotechgate also features 44,000 licensing deals and a clinical trials database containing over 1 million records from registries around the world.